When was Stellular Bio founded?

Stellular Bio was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is Stellular Bio located?

Stellular Bio is headquartered in Watertown, United States. It is registered at Cambridge, Massachusetts.

How many employees does Stellular Bio have?

As of Sep 30, 2026, the latest employee count at Stellular Bio is 12.

Is Stellular Bio a funded company?

Stellular Bio is a funded company, having raised a total of $37.5M across 10 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2016.

When was the latest funding round of Stellular Bio?

Stellular Bio's latest funding was a $***** Series A round on Jan 28, 2026, with participation from 1 investor. Its primary sector is Regenerative Medicine. In United States, the Regenerative Medicine sector has seen $35.5M in funding in 2026 to date.

Where does Stellular Bio rank among its competitors?

Stellular Bio ranks 7th amongst 126 active competitors, of which 34 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Pandorum, which secured $429K in Mar, 2026.

Who are the top competitors of Stellular Bio?

Stellular Bio's top competitors include Lineage Cell Therapeutics, Pandorum and Remegen. Among them, Pandorum secured the most recent funding round in March, 2026.

Stellular Bio - 2026 Company Profile, Team, Funding & Competitors

Stellular Bio is a series A company based in Watertown (United States), founded in 2014 by Joseph Italiano and Sven Karlsson. It operates as a Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells. Stellular Bio has raised $37.5M in funding. The company has 126 active competitors, including 34 funded and 26 that have exited. Its top competitors include companies like Lineage Cell Therapeutics, Pandorum and Remegen.

Company Details

Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells. It offers programmable logic controller platform focused on modifying the regenerative power of platelets, enabling researchers to create reengineering cell therapies.

Website: www.stellularbio.com/
Social
Email ID: *****@stellularbio.com
Phone Number: +1 **********
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2014

Location

Watertown, United States

Stage

Series A

Total Funding

$37.5M in 10 rounds

Latest Funding Round

Series A, Jan 28, 2026, $*****

Investors

Qiming & 6 more

Ranked

7^th among 126 active competitors

Employee Count

12 as on Sep 30, 2026

Similar Companies

Lineage Cell Therapeutics & 142 more

View Stellular Bio's full profile

Stellular Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PLATELET BIOGENESIS CIN: 464633412 , United States, Active	Dec 26, 999	-	11 (As on Dec 31, 2024)	-

Stellular Bio has raised a total funding of $37.5M over 10 rounds. Its first funding round was on Apr 01, 2016. Its latest funding round was a Series A round on Jan 28, 2026 for $*****. 1 investor participated in its latest round. Stellular Bio has 7 institutional investors.

Here is the list of recent funding rounds of Stellular Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 28, 2026	9302443	Series A	4567301	2087954	7657727	1547811
Mar 28, 2025	3984562	Grant (prize money)	5330193	1054140	2216029	HHS
Aug 13, 2019	6081749	Series A	2298493	4264821	3179408	Nest Bio Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Stellular Bio's funding rounds and investors

The founders of Stellular Bio are Joseph Italiano and Sven Karlsson. Derek Adams is the CEO of Stellular Bio.

Here are the details of Stellular Bio's key team members:

Joseph Italiano: Co-Founder of Stellular Bio and founder of 1 other company.
Contact Info: 2 email addresses
Sven Karlsson: Former Co-Founder of Stellular Bio and founder of 1 other company.
Contact Info: 1 email address

View details of Stellular Bio's Founder profiles and Board Members

Stellular Bio's employee count trend

Stellular Bio has 12 employees as of Sep 26. Here is Stellular Bio's employee count trend over the years:

Uncover Stellular Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Stellular Bio include Lineage Cell Therapeutics, Pandorum and Remegen. Here is the list of Top 10 competitors of Stellular Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$23M	State of California, Juvenescence & 4 others	65/100
2nd	Pandorum 2011, Bengaluru (India), Series B	Developer of regenerative medicine and 3D tissues	$52.1M	IAN Group, BTB Venture & 89 others	65/100
3rd	Remegen 2008, Yantai (China), Public	Developer of therapies for the treatment of cancer, autoimmune and eye diseases	$100M	Lilly Asia Ventures, CDG Capital & 10 others	62/100
4th	Orthofix 1980, Lewisville (United States), Public	Developer of reconstructive and regenerative solutions for bone-related conditions	-	-	61/100
5th	Avita Medical 1992, Cambridge (United Kingdom), Public	Regenerative and Respiratory Medicine product company	-	BioScience Managers, Oceania Capital Partners ... & 6 others	61/100
6th	TreeFrog Therapeutics 2018, Talence (France), Series B	Developer of stem cells and organoids using proprietary technology	$84.2M	XAnge, Leonard Green and Partners & 12 others	60/100
7th	Stellular Bio 2014, Watertown (United States), Series A	Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells	$37.5M	Qiming, Vivo Capital & 5 others	59/100
8th	Valitor 2010, Berkeley (United States), Series B	Developer of therapeutic proteins for multiple disease conditions	$38.2M	Morningside, ShangPharma Innovation & 9 others	56/100
9th	Organogenesis 1985, Canton (United States), Public	Regenerative tissue innovations for advanced wound care and surgical solutions	$30M	Spring St. Group, Eastward Capital Partners ... & 2 others	55/100
10th	TearSolutions 2013, Charlottesville (United States), Series B	Topical therapeutics for the treatment of dry eye disease	$43M	Center for Innovative Technology, VTC Ventures ... & 5 others	54/100